Project description:DIPG is a paediatric brainstem glioma with no cure. Cellular immunotherapy approaches require specific targeting of unique and tumour specific cell surface antigens, however, there is a paucity of known targets for DIPG. In this study we have used a proteomics approach to interrogate an array of patient derived DIPG cell lines to identify potential immunotherapy targets
Project description:IPF (n=20) and control (n=19) samples were obtained through the LTRC and were sequenced on an Illumina HiSeq 2000 following TruSeq RNA Sample Prep Kit v2 library preparation.
Project description:Diffuse midline glioma (DMG) is a lethal pediatric brain cancer with limited treatment options. We developed a human brainstem organoid model to study H3.3K27M-driven DMG, enabling formation of patient-like tumors with molecular heterogeneity. To characterize the resulting tumor we performed DNA methylation and compared the generated tumor with methylation data from DMG, pGBM and PFA ependymoma patients.
Project description:We report the application of high-throughput RNA-sequencing Profile of miR-203 expressing glioma U251 cells. Glioblastoma (GBM) is the most common primary malignant intracranial adult brain tumor. Allelic deletion on chromosome 14q plays an essential role in GBM pathogenesis, and this chromosome 14q site was thought to harbor multiple tumor suppressor genes associated with GBM, a region that also encodes microRNA-203 (miR-203). This study was conducted to identify whole transcriptome profile changes associated with miR-203 expression by high-throughput NGS-RNA sequencing. Total RNA samples are quantified using Nanodrop and qualified by agarose gel electrophoresis. The mRNA is enriched by oligo(dT) magnetic beads or the total RNA is depleted of rRNAs by Arraystar rRNA Removal Kit if the RNA sample is degraded or is of prokaryotic origin. We use Illumina kits for the RNA-seq library preparation, which include procedures of RNA fragmentation, random hexamer primed first strand cDNA synthesis, dUTP based second strand cDNA synthesis, end-repairing, A-tailing, adaptor ligation and library PCR amplification. Finally, the prepared RNA-seq libraries are qualified using Agilent 2100 Bioanalyzer and quantified by qPCR absolute quantification method. The sequencing is performed using Illumina Hiseq 4000.
Project description:The aim of this study is to identify by Next Generation Sequencing - RNA-seq profiling a molecular signature of Hepatocellular Carcinoma samples that correlates with survival. The samples were retrospectively derived from hepatocellular carcinoma tissue as well as non-tumor tissue from the livers of the same patients. The bioinformatical analysis of 32 pairs RNA-seq datasets were obtained from human RNAs on Illumina Hiseq-PE150. Due to the lack of biological sample duplication, this datasets were used hisat2 2.1.0 and gfold v1.1.4 for expression analysis to identify differences in gene expression between tumors and adjacent tissues. (including up- and down-regulation).
Project description:Paired WGS samples, 24 tumor/control pairs of primary CNS lymphoma, sequenced on HiSeq X Ten using Illumina TruSeq Nano DNA for library preparation.